Despite the success of CAR-T therapies for B-cell cancers and multiple myeloma, developing CAR-T therapies for solid tumors has posed more of a challenge. Failure of the CAR-T cells to multiply to high enough levels, the tumor microenvironment being immunosuppressive, and tumor cells ‘escaping’ the therapy by losing target antigen expression are just some of […]